Paroxysmal atrial fibrillation (AF) can be caused by gainof-function mutations in genes, encoding the cardiac potassium channel subunits KCNJ2, KCNE1, and KCNH2 that mediate the repolarizing potassium currents I k1 , I ks , and I kr , respectively.
A trial fibrillation (AF) is the most prevalent cardiac arrhythmia in clinical practice. AF often initially presents as transient episodes, clinically referred to as paroxysmal AF (pAF), usually self-terminating within <1 week. However, 15% of pAF patients progress to persistent and permanent forms annually. 1, 2 Diurnal variation in the timing of pAF events has been clearly demonstrated, with peak incidence at nighttime/midnight. 3, 4 The prevalence of AF increases with age, from 2% to 4% in individuals in their 60s to almost 15% at >80 years of age, significantly contributing to morbidity and mortality. [5] [6] [7] In most cases, AF occurs later in life as a result of various factors promoting structural and functional remodeling of the atria, including congestive heart failure, coronary artery disease, valvular disease, and hypertension. [8] [9] [10] Conversely, the less common early-onset AF is usually independent of additional cardiac comorbidities and shows significant heritability, with disease-causing genetic mutations as a prominent underlying cause. 11 The mechanisms by which these mutations contribute to AF fall into 3 main categories: structural remodeling that interferes with intercellular electric communication, Ca 2+ handling abnormalities that promote triggered activity, and electrical remodeling that results in aberration of atrial action potential properties. 12 Electrical remodeling of the atria underlies the majority of monogenic cases of AF described thus far. It occurs because of channelopathies, caused by mutations in genes encoding ion channels and their accessory subunits. 13, 14 In pAF, these are mostly gain-of-function mutations in potassium channels subunits KCNJ2, KCNE1, and KCNH2, responsible for the repolarizing currents I k1 , I ks , and I kr , respectively. [15] [16] [17] [18] [19] These mutations result in enhanced atrial repolarization, causing abbreviation of action potential duration, and consequentially shortening of the effective refractory period. These changes increase susceptibility to AF because they create a vulnerable arrhythmogenic substrate capable of sustaining multiple circuit reentry. 20 Through molecular genetic studies followed by electrophysiological analyses in Xenopus oocytes, we now show that early-onset nocturnal pAF is caused by a dominant mutation in KCND2, encoding the α-subunit of the Kv4.2 potassium channel which underlies the transient outward potassium current, I to .
MATERIALS AND METHODS
The data, analytic methods, and study materials will be made available to other researchers for the purpose of reproducing the results or replicating the procedure. The authors declare that the data supporting the findings of this study are available within this article, its Data Supplement, and on request. The experimental methods are provided in the Data Supplement. The study was approved by the Soroka Medical Center Institutional Review Board (approval number 5071G) and the Israel Ministry of Health National Helsinki Committee (approval number 920100319). DNA was extracted from peripheral blood or saliva after written informed consent was obtained from all participants or their legal guardians. Clinical phenotyping was done by senior cardiologists.
RESULTS
Three generations of a family of Jewish-Persian descent presented with autosomal dominant early-onset pAF, affecting 9 family members ( Figure 1A ). Age at onset of symptoms was 22 to 50 years (38.6±12.1). In all affected individuals, pAF presented as recurrent self-terminating palpitations that were predominantly nocturnal. ECG recordings in sinus rhythm of affected family members were without evidence of Brugada syndrome type 1, 2, or 3 patterns. Several of the affected family members were under routine treatment of flecainide and therefore presented a negative flecainide test. Available echocardiography results excluded signs of cardiomyopathy or any structural abnormalities; additional cardiac comorbidities or other noncardiac disease-associated phenotypes have been excluded as well. It is noteworthy that 2 of the patients (II-5, II-3), presenting with the most severe phenotype, are currently effectively treated with flecainide, following failed attempts or side effects of treatment with amiodarone. Clinical findings of the affected individuals are presented in Table. In detail, the proband (II-5) first demonstrated symptoms of pAF at the age of 22 years. ECG during AF episode recorded average heart rate of 90 beats per minute with no additional findings ( Figure 1B) . Before medical therapy, symptoms included frequent self-terminating palpitations with mostly nocturnal onset, with dyspnea and fatigue during episodes. On administration of flecainide, episodes almost entirely ceased, currently (aged 55 years) occurring 1 to 2× a year. The proband's son (III-1) described similar clinical features, including recurrent palpitations predominantly nocturnal and at postprandial states. Most episodes were self-terminating, although at least 1 episode lasted 48 hours. Holter monitoring (24 hours) revealed several episodes of nocturnal supraventricular extra systoles. The proband's sister (II-8) experienced rare episodes of palpitations, usually self-terminating; however, in 1 episode that required hospitalization, ECG recordings revealed AF with slow ventricular response of 60 beats per minute, which eventually spontaneously converted to sinus rhythm. Her son (III-2), who presented with frequent episodes of self-terminating palpitations, was not available for further analysis. The proband's brother (II-3) described frequent episodes of palpitations occurring on a daily basis, off medications. All episodes were nocturnal and self-terminating. In 1 episode that required hospitalization, ECG recordings demonstrated AF, with heart rate of 152 beats per minute. Catheter ablation (focal pointby-point radiofrequency) of pulmonary veins was temporarily successful, yet pAF recurred after 6 months. The proband's sister (II-1) reported episodes of palpitations. Most terminated spontaneously, but on at least 2 occasions required hospitalization. Holter monitoring (24 hours) revealed a nocturnal episode of atrial tachycardia of 146 beats per minute for 3 to 7 beats; however, AF was not documented at this time. A third sister of the proband (II-2) also experienced self-terminating palpitations with increasing frequency, occurring monthly. One episode required hospitalization. ECG during that episode recorded AF with average ventricular rate of 150 beats per minute. The patient converted to sinus rhythm after administration of intravenous metoprolol and oral loading of propafenone. Another brother of the proband (II-4) had episodes of palpitations 5 to 6× a year. Most episodes occurred during sleep and selfterminated. ECG recordings during such an episode demonstrated AF with ventricular rate of 155 beats per minute. At least 7 episodes (one of which lasted for 3 days) required hospitalization and were treated with direct current cardioversion. The proband's mother (I-1) initially presented with symptoms of spontaneously terminating palpitations, occurring during sleep and during the day on a regular basis. She was later diagnosed with pAF and supraventricular tachycardia. ECG during episodes demonstrated slow ventricular rate of 88 beats per minute, yet additional ECG studies recorded ≈160 beats per minute on different occasions. Over time, episodes became more frequent, reaching 2 to 3 epi- sode per day at the age of 64 years. In her late 70s, this patient was diagnosed with permanent AF. It should be noted that individual II-10 had AF, yet the clinical presentation was different than in the other family members: he had only 2 episodes (compared with dozens of episodes in affected family members), with a later onset (between the ages of 60 and 65 years). Moreover, the AF was not self-terminating and required treatment by direct current cardioversion. This individual suffers from several known risk factors of AF, including obesity, obstructive sleep apnea, impaired glucose tolerance, and mild hypertension. Moreover, in contrast to other members of the family, the onset of his episodes was not nocturnal or mediated by vagal stimulation. Taking into consideration the overall occurrence of AF in the general population above the age of 60 and the unique clinical presentation of this individual, we decided to exclude II-10 from our criteria for the familial phenotype of early-onset pAF.
Genetic Analysis
Analysis of whole-exome sequencing data of subject II:5 excluded all known variants previously described as causing AF according to the Human Gene Mutation Database or mutations in any of the genes previously associated with cardiac arrhythmias, suggesting a novel mutation underlying the disease in this kindred. Linkage analysis, performed on all available DNA samples, identified 5 genomic loci shared between all affected individuals and none of the unaffected ones (Table I in the  Data Supplement) , with a maximal logarithm of odds score of 2.4. Whole-exome sequencing data of subject II:5 was then analyzed using the filtration cascade described in detail in the Materials and Methods section. After filtration, only 4 rare or novel protein-altering variants remained within the genomic loci identified in the linkage analysis (Table II in the Data Supplement) . Of these variants, only one was highly conserved among species and showed expression in cardiac tissue 21 : c.1341C>G in KCND2, encoding the Kv4.2 potassium channel. Sanger sequencing validated segregation of the mutation in the family as expected for autosomal dominant heredity (Figure 2A ). This mutation results in a p.S447R substitution of a highly conserved serine residue in the cytoplasmic C-terminal domain of the channel ( Figure 2B and 2C). The variant has not been identified in any of the exomes sequenced in the ExAC browser (http://exac.broadinstitute.org) and in only 1 of 245 510 genomes sequenced in the gnomAD genome browser (http://gnomad.broadinstitute.org).
Functional Studies of Kv4.2-S447R
Patient-derived or CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/clustered regularly interspaced short palindromic repeat-associated 9)-generated mutant cardiomyocytes differentiated from induced pluripotent stem cells are immature, and as such lack I to currents 22 ; therefore, patch-clamp experiments could not be done in this study. Thus, to evaluate the effects of the p.S447R mutation on Kv4.2 function, we studied channel activity using the 2-electrode voltage-clamp technique in Xenopus laevis oocytes. As cardiac Kv4.2 channels interact with KChIP2 (Kv channel-interacting protein 2), 23 all our experiments were performed in the presence of excess amounts of this auxiliary protein. To test the effect of the p.S447R mutation on channel voltage-dependent activation and inactivation, a standard voltage protocol was applied ( Figure 3A ). Significant decrease in the rate of inactivation was observed for the mutated channel. For example, the time constant of inactivation (τ) at 70 mV for the wild-type channel and for the mutant channel was 27.4±1.5 and 40.7±2.8 ms, respectively ( Figure 3B ). When both channels were coexpressed, mimicking the heterozygous state, as found in our patients, an intermediate rate was observed (35.7±2.3 ms; Figure 3B ). Slower inactivation rate for the p.S447R mutant was observed across all tested potentials ( Figure 3C ). No change was detected in the peak current/voltage relationship of Kv4.2 because of the introduction of the mutation ( Figure 3D) , suggesting a null effect on the half-maximal activation voltage (V 0.5 ). Similarly, no significant difference was found at the half-inactivation potential (V 0.5 ) values for both channels (−54.0±0.9 and −54.5±1.2 mV for the wild-type and the S447R mutant, respectively; Figure 4A ). Recovery from inactivation in both channels was similar but not identical ( Figure 4B ). The time constant of recovery from inactivation was slightly smaller in the mutant channel compared with the wild-type channel (27.2±1.3 and 32.6±2.2 ms, respectively; P<0.05). Both the slower inactivation and the slightly faster recovery from inactivation contribute to an overall gain-of-function effect of the mutation on Kv4.2 channel activity.
It has been previously shown that the PKC activator phorbol 12-myristate 13-acetate suppresses both Kv4.2 currents and native I to . 24 The decrease in Kv4.2 currents because of PKC activation was shown to result from a reduction in surface expression of the channel. 25, 26 Kv4.2-Ser447 was identified as 1 of the 2 PKC phosphorylation sites that mediate the PKC-dependent attenuation of membrane localization and stabilization of Kv4.2. 25, 26 To study the effect of the p.S447R mutation on Kv4.2 current levels during phosphorylation by PKC, we performed a current inhibition assay using phorbol 12-myristate 13-acetate. Peak currents of oocytes expressing Kv4.2, Kv4.2-S447R, and a combination of both (Kv4.2+Kv4.2-S447R) were measured before and after 30-minute incubation in phorbol 12-myristate 13-acetate ( Figure 5 ). As expected, significant reduction was observed in wild-type channels current (38±6% of initial current). However, current was only mildly affected in the p.S447R mutant channel (83±7% of initial current) and slightly more when the wild-type and the mutant channels were coexpressed (71±7% of initial current), suggesting an impaired response to PKC and enhanced membrane expression as a result of the mutation.
Functional Studies of the Kv4.3-Kv4.2 Hybrid Channel
It has been previously shown that to create a mature functional channel, Kv4.2 α-subunits can assemble into homotetramers or coassemble with α-subunits of Kv4.3 creating heterotetramers. 27 Because both subunits are expressed in the human heart, we set out to examine whether the effects of the p.S447R mutation on Kv4.2 channels alone are also evident on heterotetramers created by a combination of Kv4.2 and Kv4.3. To that end, we created a hybrid channel where the amino-terminal of Kv4.2 is linked to the carboxyl-terminal of Kv4.3 via a 10Q linker (Materials and Methods). Voltage-dependent activation and inactivation were measured by the voltage protocol described earlier ( Figure 3A) . A small yet significant decrease in the rate of inactivation of the hybrid channel containing the p.S447R mutation was observed across all tested potentials ( Figure 6A ). For example, the time constant of inactivation (τ) at 70 mV for the wildtype Kv4.3-Kv4.2 channel and for the mutant channel was 75.9±1.2 and 80.6±1.1 ms, respectively (P<0.005). Current inhibition assay using phorbol 12-myristate 13-acetate was repeated to test the effect of the p.S447R mutation on phosphorylation by PKC in the wild-type versus mutant Kv4.3-Kv4.2 hybrid channel ( Figure 6B ): significant reduction in currents was observed in wildtype Kv4.3-Kv4.2 channels (52±6% of initial current). The current was significantly (P<0.05) less affected in the mutant channel, showing a smaller decrease in peak currents (72.2±6% of initial current). These observations support the results obtained in measurements of Kv4.2 channel alone and demonstrate that the p.S447R mutation affects also Kv4.3-Kv4.2 heterotetramers. 
DISCUSSION
Through molecular genetic studies of a 3-generation family with 9 affected individuals ( Figure 1A) , we show that a dominant gain-of-function mutation in KCND2, encoding the pore-forming (α) subunit of the Kv4.2 potassium channel, causes pAF. The p.S447R mutation results in the substitution of a highly conserved serine residue in the cytoplasmic C-terminal domain of the channel (Figure 2B and 2C ). Electrophysiological characterization of the mutation in Xenopus oocytes revealed that the mutation affects both the kinetic properties of the channel and its regulation by PKC. The mutant channel displayed prolonged time constant of inactivation ( Figure 3B and 3C) and a slightly shorter time constant of recovery from inactivation ( Figure 4B) , compared with the wild-type channel. Furthermore, the Kv4.2-S447R mutant displayed significantly smaller response to PKC activation ( Figure 5 ). This is in line with previous studies whereby the inability of Kv4.2 to undergo phosphorylation after mutations of its 2 phosphorylation sites (Ser 447 and Ser 537 ) to alanine resulted in a significant increase in the surface expression of Kv4.2. 25 These effects of the mutation contribute to a cumulative gain of function in the overall activity of the channel. The heterozygous state, mimicked by coexpression of both wild-type and mutant channels, displayed a gain-of-function effect, much like the mutated channel, in line with the dominant mode of inheritance of this disease. These results suggest that the gain-of-function phenotype is manifested by an increase in both the number of available channels and the magnitude of current that each channel is capable of conducting on activation. Endogenously, the effect of PKC on the channel is mediated by α-adrenergic receptor stimulation. 28 It is likely that in the patients, membrane expression of the Kv4.2 channel is increased as a result of impaired response to adrenergic stimulation.
In the heart, Kv4.2 α-subunits can assemble into homotetramers or coassemble with α-subunits of Kv4.3 creating heterotetramers. 27 These tetramers interact with Peak currents were measured at 70 mV using the voltage-clamp protocol as in Figure 3A , before and after 30-min incubation with 25 nmol/L phorbol 12-myristate 13-acetate (PMA). Current following incubation was normalized to initial current for wild-type Kv4.2 channels (n=14), mutant Kv4.2-S447R channels (n=16), and an equimolar combination of Kv4.2+Kv4.2-S447R channels (n=9). All oocytes were injected with excess levels of KChIP2 (Kv channelinteracting protein 2). ***P<0.0001; **P<0.005. Figure 3A , before and after 30-min incubation with 25 nmol/L phorbol 12-myristate 13-acetate (PMA). Current following incubation was normalized to initial current for wild-type Kv4.3-Kv4.2 channels (n=12) and mutant Kv4.3-Kv4.2-S447R channels (n=13). All oocytes were injected with excess levels of KChIP2 (Kv channel-interacting protein 2). **P<0.005, *P<0.05.
additional accessory subunits, giving rise to the repolarizing transient outward potassium current I to . 23 I to is responsible for the rapid phase of repolarization immediately after the depolarization upstroke, thereby setting the initial potential of the plateau phase and governing its duration and amplitude. 29 In humans, the principal α-subunit contributing to I to is Kv4.3. 30 It is thus important to note that the effect p.S447R exerts on heterotetramers assembled with subunits of Kv4.3 is similar to its effect on Kv4.2 homotetramers. Hence, it is plausible that the p.S447R mutation in Kv4.2 leads to a more significant effect on I to by acting on Kv4.3 as well. Thus, we propose that the gain-of-function effect of the p.S447R mutation in Kv4.2 results in enhanced cardiac I to currents. Our results are in agreement with previous studies on sporadic cases that implicated I to in the pathogenesis of AF. 31, 32 We propose that enhanced I to leads to abbreviation in atrial action potential, as previously shown in studies on animal models. 33 This lends further support to the prevailing dogma that AF can be caused by enhanced potassium currents leading to action potential duration abbreviation and a reduction in effective refractory period, creating a vulnerable substrate capable of sustaining reentry. 15 It has been previously shown that gain-of-function effects on I to are associated with the pathogenesis of Brugada syndrome, 34, 35 which was absent in all of our test subjects per ECG and negative flecainide tests. Unlike the channel subunits described in studies associating I to with Brugada syndrome (Kv4.3, MinK-related peptide 2 -MiRP2), the overall expression of Kv4.2 in the human heart is modest. Moreover, the Kv4.2 channel shows relatively lower expression in the ventricles compared with other regions in the heart. 21, 36 This might suggest a differential effect of gain of function in the atrial I to current compared with the ventricular one. This notion is further supported by the lack of any QT abnormalities in our patients, indicating an atrial-specific phenotype.
The clinical presentation in our patients is characterized by paroxysms of AF, described by the patients as recurrent episodes of irregular palpitations which spontaneously terminate. All affected individuals had predominantly nocturnal onset of symptoms (Table) . This is in line with previous studies of the circadian variation of pAF, reporting high incidence of nocturnal (nighttime/ midnight) pAF onset. 3, 4, 37, 38 Interestingly, several independent studies have identified Kv4.2 as one of few cardiac channels displaying circadian expression pattern: both mRNA and protein levels of Kv4.2 exhibit circadian variation in murine hearts, with a substantial ≈2-fold increase in expression during the light period, as well as corresponding increased I to . [39] [40] [41] As circadian-regulated genes are mostly evolutionary conserved, 42, 43 and as the light period in mice is regarded as equivalent to nighttime in humans, [43] [44] [45] it is possible that the expression of human cardiac Kv4.2 is also upregulated nighttime in a circadian-clock-dependent manner. Although this hypothesis is clearly speculative at present, it may suggest that the nocturnal occurrence of the arrhythmia in our patients might be attributed to the gain-of-function mutation in Kv4.2 in conjunction with nighttime overexpression of Kv4.2, leading to increased I to currents, facilitating a readily available arrhythmogenic substrate for reentry.
It is also noteworthy that several expression studies performed on human cardiac tissue samples show that Kv4.2 transcripts are relatively abundant in regions governing the autonomic innervation of the heart, namely the sinoatrial and atrioventricular nodes. 36, 46 Although the specific role of the Kv4.2 transcripts in these regions remains unclear, given the pivotal role of the autonomic nervous system in pAF, it is plausible that the p.S447R mutation contributes to the nocturnal onset of symptoms seen in our patients by interfering with the normal effect of autonomic innervation on the heart. Two of the patients, presenting with the most severe phenotype (II-5, II-3), are currently treated with flecainide for symptoms of pAF. Flecainide was beneficial in those patients following failed attempts of treatment with amiodarone. Interestingly, a past study examining the effects of various antiarrhythmic drugs on voltage-gated potassium channels showed that, compared with other channels, Kv4.2 is highly sensitive to flecainide, which significantly decreases Kv4.2 currents. Moreover, it has been shown that flecainide is a highly potent I to blocker in rats. 47, 48 Conversely, under the influence of amiodarone, no reduction in Kv4.2 currents was detected, with marked increase in currents in some of the conditions tested. 48 Finally, our data, combined with previous studies, imply new venues for treatment of AF: it has been previously shown that blockage of I to can lead to termination of high-frequency reentry sources (rotors) in conditions simulating AF in human atrial cells. The proposed mechanism underlying this effect was prolongation of the plateau phase of the action potential. 49 Given the atrial-specific phenotype in our patients, targeting the atrial I to using selective Kv4.2 blockers might constitute a novel strategy for pharmacological intervention in pAF in general or nocturnal pAF in particular, while avoiding the characteristic adverse effects of antiarrhythmic drugs on ventricular repolarization.
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